In a recent interview, Soroush Rais-Bahrami, M.D., discussed key findings from a post-hoc subgroup analysis of the SPOTLIGHT trial that examined the use of the PET imaging agent 18F-flotufolastat (Posluma) in African American men.
For African Americans with suspected prostate cancer (PCa) recurrence, the PET imaging agent 18F-flotufolastat (Posluma) provided a 93 percent patient-level detection rate (DR) that was six percent higher than that reported for other patients in the recent SPOTLIGHT trial.
Researchers also noted that 18F-flotufolastat had a 67 percent DR for African American patients with a prostate-specific antigen (PSA) level < 0.5 ng/mL and a 100 percent DR for those with a PSA level > 10 ng/mL in this patient population, according to the post-hoc analysis of the SPOTLIGHT trial that was recently published in Advances in Radiation Oncology.
In a recent interview, Soroush Rais-Bahrami, M.D., the lead author of the study, noted some small differences in regional detection rates between African Americans and other patients but said the findings were largely similar otherwise for the use of Posluma (Blue Earth Diagnostics) in diagnosing PCa recurrence.
“The findings holding true and being validated in large part both with imaging and histopathologic confirmation really make this new FDA-approved PSMA PET imaging agent valid in all populations of men, specifically African Americans as well as non-African American men included in the study,” maintained Dr. Rais-Bahrami, a professor in the Departments of Urology and Radiology at the University of Alabama School of Medicine in Birmingham, Ala.
Dr. Rais-Bahrami also noted that African American men comprised 17 percent of the SPOTLIGHT study cohort, nearly double the rate of African American participation reported in oncology clinical trials from 2010 to 2021.
“This shows promise that clinical trials, specifically in the realm of cancer, can have a good diversity of enrollment in terms of subjects. One of the real elements of our focus in terms of performing clinical trials should be sure to encourage not only diversity of race … but also different areas regionally throughout the country and internationally as well as different sites of practice to really reach patients with different points of access, socioeconomic status, race, ethnicity and cultural factors that may play a large role in their overall medical and specifically, in this case, cancer care,” emphasized Dr. Rais-Bahrami.
(Editor’s note: For related content, see “Emerging Research at SNMMI Examines 18F-Flotufolastat in Managing Primary and Recurrent Prostate Cancer,” “Can Targeted PSMA PET/CT Guided Radiotherapy Have an Impact for Oligometastatic Prostate Cancer?” and “Study: PSMA PET/CT More Advantageous than MRI for Locoregional Staging of Prostate Cancer.”)
For more insights from Dr. Rais-Bahrami, watch the video below.
Study: AI-Generated ADC Maps from MRI More Than Double Specificity in Prostate Cancer Detection
June 5th 2025Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
What a New PSMA PET/CT Study Reveals About Local PCa Treatment and High-Risk Recurrence
May 16th 2025For patients at high-risk for biochemical recurrence of prostate cancer, PSMA PET/CT findings revealed that 77 percent had one or more prostate lesions after undergoing local radiation therapy or radical prostatectomy, according to a recent study.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.